Researchers have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440 may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.
Researchers have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440 may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.